2024 Peer Review | An Analysis of 20 Independently Performed Assays to Measure Homologous Recombination Deficiency (HRD) in Ovarian Cancer: Findings from the Friends’ HRD Harmonization Project Read more
2024 Peer Review | Bridging research and practice: enhancing regulatory decisions with pragmatic clinical trials in oncology Read more
2024 Peer Review | Evaluation of Real-World Tumor Response Derived From Electronic Health Record Data Sources: A Feasibility Analysis in Patients With Metastatic Non–Small Cell Lung Cancer Treated With Chemotherapy Read more
2024 Peer Review | An evaluation of novel oncology approvals with a PMR/C for assessing data in racial and ethnic populations underrepresented in premarket clinical trials Read more
2024 Peer Review | Advancing Evidence Generation for Circulating Tumor DNA: Lessons Learned from A Multi-Assay Study of Baseline Circulating Tumor DNA Levels across Cancer Types and Stages Read more
2024 Peer Review | Accelerating the development of genetically engineered cellular therapies: a framework for extrapolating data across related products Read more
2023 Peer Review | An Analysis of Dosing-Related Postmarketing Requirements for Novel Oncology Drugs Approved by the U.S. Food and Drug Administration, 2012–2022 Read more
Peer Review | Sponsor Perspectives on the Impact of the COVID-19 Pandemic on Interventional Cancer Clinical Trial Protocols and Data Quality Read more
2023 Peer Review | Real-world response endpoints in patients with mNSCLC treated with chemotherapy across real-world datasets. Read more
2022 Peer Review | Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trials Read more
